Shanti Aya, Teo Jeremy, Stefanini Cesare
Department of Biomedical Engineering, Khalifa University of Science and Technology, Abu Dhabi, P.O. Box 127788, UAE.
Division of Engineering, New York University Abu Dhabi, Abu Dhabi, P.O. Box 129188, UAE.
Pharmaceutics. 2018 Dec 15;10(4):278. doi: 10.3390/pharmaceutics10040278.
The current drug development practice lacks reliable and sensitive techniques to evaluate the immunotoxicity of drug candidates, i.e., their effect on the human immune system. This, in part, has resulted in a high attrition rate for novel drugs candidates. Organ-on-chip devices have emerged as key tools that permit the study of human physiology in controlled in vivo simulating environments. Furthermore, there has been a growing interest in developing the so called "body-on-chip" devices to better predict the systemic effects of drug candidates. This review describes existing biomimetic immune organs-on-chip, highlights their physiological relevance to drug development and discovery and emphasizes the need for developing comprehensive immune system-on-chip models. Such immune models can enhance the performance of novel drug candidates during clinical trials and contribute to reducing the high attrition rate as well as the high cost associated with drug development.
当前的药物研发实践缺乏可靠且灵敏的技术来评估候选药物的免疫毒性，即它们对人体免疫系统的影响。这在一定程度上导致了新型候选药物的高淘汰率。芯片器官装置已成为在可控的体内模拟环境中研究人体生理学的关键工具。此外，人们对开发所谓的“芯片人体”装置以更好地预测候选药物的全身效应的兴趣与日俱增。本综述描述了现有的仿生免疫芯片器官，强调了它们在药物研发和发现中的生理相关性，并强调了开发综合免疫系统芯片模型的必要性。这样的免疫模型可以提高新型候选药物在临床试验中的表现，并有助于降低高淘汰率以及与药物开发相关的高成本。
